Toggle Nav

NVP-BEP800

In stock
Catalog No.
A4064
Oral Hsp90β inhibitor, novel, fully synthetic
Grouped product items
SizePriceStock Qty
5mg
$110.00
In stock
10mg
$190.00
In stock
25mg
$410.00
In stock
100mg
$960.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

NVP-BEP800 is a fully synthetic, orally bioavailable inhibitor of Hsp90 with IC50 value of 58nM [1].

NVP-BEP800 binds to the N-terminal ATP-binding pocket of Hsp90. In a competitive binding fluorescence polarization assay, NVP-BEP800 inhibits Hsp90β with IC50 value of 58nM. And to other 20 protein kinases, NVP-BEP800 shows a IC50 of >10μM. In BT-474 cells and A375 cells, NVP-BEP800 causes the Hsp90-p23 dissociation and client protein degradation (ErbB2) as well as the reduction of client protein phosphorylation (phospho-Akt). Degradation of these oncogenic client proteins results in tumor cell growth arrest and death. NVP-BEP800 inhibits proliferation of tumor cells with an average GI50 of 245nM. And in 46 primary human tumors including small cell lung, mammary cancer and melanoma, the mean IC50 is 750nM. Additionally, treatment of NVP-BEP800 induces apoptosis in human breast cancer cell lines. The antitumor efficacy of NVP-BEP800 is also observed with a dose of 15 or 30 mg/kg/d in A375 xenograft-bearing mice as well as in BT-474 breast cancer xenografts [1].

References:
[1] Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19.

Chemical Properties

StorageStore at -20°C
M.Wt480.4
Cas No.847559-80-2
FormulaC21H23Cl2N5O2S
Solubility≥24.7 mg/mL in DMSO with ultrasonic and warming, <1.98 mg/mL in H2O, ≥16 mg/mL in EtOH with gentle warming
Chemical Name2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
SDFDownload SDF
Canonical SMILESCCNC(=O)C1=CC2=C(N=C(N=C2S1)N)C3=CC(=C(C=C3Cl)Cl)OCCN4CCCC4
Shipping ConditionEvaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Protocol

Kinase experiment [1]:

Competitive binding fluorescent polarization assay

Recombinant Hsp90β, TAMRA-radicicol, or various concentrations of NVP-BEP800 was added in assay buffer (50 mM TRIS pH 7.4, 5 mM MgCl2, 150 mM KCl and 0.1% CHAPS), mixed and incubated at room temperature for 30 ~ 45 mins prior to reading. The 2D-FIDA-based HTS assay based on confocal technologies monitored the decreased fluorescence polarization on displacement of the high affinity ligand TAMRA-radicicol from Hsp90β by NVP-BEP800. The concentration of NVP-BEP800 which inhibited Hsp90β by 50% was determined from the competition curve.

Cell experiment [1]:

Cell lines

BT-474 cells

Preparation method

The solubility of this compound in DMSO is limited. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months.

Reacting condition

50 ~ 500 nM; 24 hrs

Applications

In BT-474 cells, NVP-BEP800 concentration-dependently decreased phospho-Akt (Ser473) and ErbB2 levels. At the dose of 500 nM, phosphorylation of Akt at Ser473 was not detectable, and lower levels of Akt and ErbB2 were also detected.

Animal experiment [1]:

Animal models

Mice bearing breast cancer BT-474 cell xenografts

Dosage form

15 or 30 mg/kg/day; p.o.

Applications

In mice bearing breast cancer BT-474 cell xenografts, NVP-BEP800 dose-dependently increased Hsp90-p23 complex dissociation and lowered the levels of steady-state ErbB2, phospho-Akt as well as phospho-S6. NVP-BEP800 induced 38% tumor regression at dose of 30 mg/kg/day and a T/C value of 36% at dose of 15 mg/kg/day.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Massey AJ, Schoepfer J, Brough PA, Brueggen J, Chène P, Drysdale MJ, Pfaar U, Radimerski T, Ruetz S, Schweitzer A, Wood M, Garcia-Echeverria C, Jensen MR. Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800. Mol Cancer Ther. 2010 Apr;9(4):906-19.

Biological Activity

Description NVP-BEP800 is a novel, fully synthetic, oral inhibitor of Hsp90β with IC50 value of 58 nM.
Targets Hsp90β          
IC50 58 nM          

Quality Control